Published data was reanalyzed using the same analysis pipeline (Methods). was amplified. Additional PCR product was verified by sequencing. The qPCR primers are 5′-CCCAGGTACCAGCAGACC-3′ and 5′-TCCAGGAGATGTAACTCTAATCCA-3 [9]. Right: the qPCR products were run on the gel and their identity was confirmed by PluriSln 1 sequencing (data not display).(TIF) pgen.1008754.s002.tif (765K) GUID:?AAFFFBA6-266A-4DCF-8526-5AA4E70431E6 S3 Fig: Principal component analysis (PCA) on control and FSHD2 myoblast differentiation time-course. (A) PCA with Personal computer1, Personal computer2 and PluriSln 1 Personal computer3 for FSHD2 and control myoblasts from tibialis anterior. Personal computer2 further clarifies the manifestation variance across differentiation. (B) PCA with Personal computer1, Personal computer2, and Personal computer3 for settings from tibialis anterior (TA) and settings from quadricep (quad). Personal computer2 and Personal computer3 combined clarify the manifestation variance for muscle mass resource and sex. Gene manifestation level was measured each day for duplicates by using RNA-seq. Cell types are labeled by shape, and time-points are labeled by color.(TIF) pgen.1008754.s003.tif (658K) GUID:?E7B04A8C-C706-480C-ACAE-AE4F9C4FAA95 S4 Fig: Principal component analysis (PCA) on control and FSHD2 myoblast differentiation time-course. (A) PCA with Personal computer1, Personal computer2, and Personal computer3 for FSHD2, settings from tibialis anterior (TA) and settings from quadricep (quad). Personal computer2 further clarifies the manifestation variance across differentiation. (B) PCA with Personal computer1, Personal computer3, and Personal computer4 for FSHD2, settings from tibialis anterior (TA) and settings from quadricep (quad). Personal computer3 and Personal computer4 account for variance in gene manifestation between FSHD2 and control samples. Gene manifestation level was measured each day for duplicates by using RNA-seq. Cell types are labeled by shape, and time-points are labeled by color.(TIF) pgen.1008754.s004.tif (642K) GUID:?7A9D89EA-8762-45B9-BE57-84330B28E52A S5 Fig: Genes variable across time but not between FSHD and control form two clusters. (A) Cluster 1 gene decrease during differentiation. (B) Cluster 2 gene increase during differentiation. (C) Quantification of differentiation index in myosin weighty chain1(MYH1) stained control-2 and FSHD2-2 myoblast cell lines for days 0, 3 and 5 of differentiation. Differentiation index PluriSln 1 PluriSln 1 is definitely defined as the number of nuclei in myotubes expressing MYH1 divided by the total quantity of nuclei inside a field. We identified the differentiation index by counting at least 600 nuclei from 3 random fields on each coverslip which was fixed at indicated days after differentiation. Myotubes with any detectable MYH1 transmission are considered positive, and the transmission strength of MYH1 staining is PluriSln 1 not taken into consideration. Statistically significant delay of differentiation was observed in FSHD myocytes compared to the control used on day time 3 (~70% as opposed to 90%). On day time 5, differentiation index is still reduced FSHD than control but the difference is definitely no longer statistically significant. (D) Representative images of differentiation marker MYH1 (reddish) staining of days 0, 3 and 5 of differentiation in control-2 and FSHD2-2 cells. Pub, 10 m. DAPI is in blue.(TIF) pgen.1008754.s005.tif (1.5M) GUID:?0AE7779C-26E7-4771-A75D-A5C903135A03 S6 Fig: Venn diagram of FSHD-induced genes from this study and published FSHD and DUX4 CACNB3 induced genes. (A) Overlap of 53 of the 54 genes upregulated during FSHD2 differentiation time-course from myoblasts to myotubes compared to 625 genes upregulated in myoblasts with doxycycline induced manifestation [25] and to 587 genes upregulated in expressing myotubes over non-expressing myotubes [22]. Published data was reanalyzed using the same analysis pipeline (Methods). (B) Overlap of 54 genes upregulated during FSHD2 differentiation time-course from myoblasts to myotubes compared to 91 genes upregulated in FSHD main myoblasts and myotubes compared to control [20]. Published data was reanalyzed using the same analysis pipeline (Methods).(TIF) pgen.1008754.s006.tif (431K) GUID:?A8527D86-6848-41EF-AF35-2BF46D54690C S7 Fig: Fold change heatmap of FSHD-induced genes for FSHD2-1 and FSHD2-2 vs control-1 and control-2. All logFC with p <0.05 are shown for comparisons of FSHD2 to control for each day of differentiation.(TIF) pgen.1008754.s007.tif (1.4M) GUID:?B230C619-E0F9-499E-82CC-642DD4B82D72 S8 Fig: Overview of single-cell and single-nucleus samples from Fluidigm and comparison with time-course. (A) Summary of single cells and single nuclei collected for sequencing. Single cells from myoblasts were selected to be and and in FSHD2 myotubes at days 3 and 7 of differentiation. (A) DUX4 RNAScope probe design. Schematic diagrams of mRNA (NM_001306068.2) and its isoform DUX4s and homologs (and mRNA. The "Orange" homologous sequences are different enough and would not be recognized by our probes. To minimize the crossdetection of or but missing in (top) or (middle and bottom rows) RNAScopes are combined with immunofluorescence staining using antibody against DUX4 protein in FSHD2 myotubes at day 7 of differentiation. Myotubes made up of positive or RNA transcript signals are also positive for DUX4 protein staining. or RNAScope transmission, green; DUX4.